NR1H4 and metabolic dysfunction-associated steatohepatitis: Adding to the complexity is the role of obeticholic acid (OCA), an FXR ligand recently approved for PBC treatment, which is associated with a further increase in LDL-c, especially in subjects with concurrent NASH [72]; there are controversial data on this matter come from trials dedicated to individuals exclusively affected by PBC [73,74].